help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2005-2411
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berk, E. S.
Right arrow Articles by Albu, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berk, E. S.
Right arrow Articles by Albu, J. B.
Related Collections
Right arrow Metabolism
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 10 4099-4106
Copyright © 2006 by The Endocrine Society

Metabolic Inflexibility in Substrate Use Is Present in African-American But Not Caucasian Healthy, Premenopausal, Nondiabetic Women

Evan S. Berk, Albert J. Kovera, Carol N. Boozer, F. Xavier Pi-Sunyer and Jeanine B. Albu

New York Obesity Research Center, St. Luke’s-Roosevelt Hospital Center, Columbia University, New York, New York 10025

Address all correspondence and requests for reprints to: Jeanine Albu, M.D., New York Obesity Research Center, St. Luke’s-Roosevelt Hospital Center, 1111 Amsterdam Avenue, Department of Medicine, Babcock Building Room 1031, New York, New York 10025. E-mail: jba1{at}columbia.edu.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Context: There is an increased prevalence of obesity and insulin resistance in African-American compared with Caucasian females. Metabolic inflexibility (MI) is the inability to switch the use of lipids and carbohydrates in the peripheral tissue (i.e. muscle) based upon substrate availability.

Objective: We examined whether MI exists in African-American females.

Main Outcome Measures and Design: We measured substrate use differences during eucaloric, macronutrient-manipulated diets [high fat (50% fat, 35% carbohydrate, 15% protein) vs. low fat (30% fat, 55% carbohydrate, 15% protein)] between Caucasian and African-American women. We also compared differences in substrate use in response to insulin infusion during two-step pancreatic-euglycemic clamps and epinephrine infusion during lipolysis studies. In each study, similar groups of Caucasian and African-American women were compared.

Results: Caucasians had significantly higher fat oxidation (FO) (P = 0.01) and lower carbohydrate oxidation (P < 0.01) during the high-fat vs. low-fat diet, whereas no significant differences were observed in African-Americans. The African-American women also failed to significantly suppress FO during the second step of the pancreatic-euglycemic clamp despite a doubling of their fasting plasma insulin and failed to increase their FO or decrease their carbohydrate oxidation in response to epinephrine infusion as much as Caucasian women did. The response of free fatty acid turnover rates to insulin and epinephrine stimulation was similar between races.

Conclusion: The impaired substrate use observed in African-American women during these three studies demonstrates the existence of MI and may contribute to their greater prevalence of obesity and insulin resistance.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
WITH THE INCREASED obesity epidemic in the United States, new physiological dysregulations have been observed. One such dysregulation is metabolic inflexibility (MI). MI was identified and extensively studied by Kelley and colleagues (1, 2, 3, 4, 5) in obese and type 2 diabetics and is characterized by an absence of increased fat oxidation in skeletal muscle during fasting conditions and the impaired ability to switch from fat to carbohydrate oxidation in response to insulin. Healthy populations (6, 7, 8) have been shown to switch their fuel use based upon substrate availability; however, within healthy individuals, the degree of metabolic flexibility varies (9). Myocytes obtained from healthy, lean males were found to be more inflexible in vitro (decreased fat oxidation suppression with glucose and a smaller increase in fat oxidation with palmitate) with increased percent body fat and free fatty acid (FFA) levels and decreased insulin sensitivity (9). Insulin resistance is hypothesized as one mechanism for MI (4, 5).

African-American females have a higher obesity prevalence than age-matched Caucasians (10). Nearly half of the African-American females aged 30–44 yr are overweight, whereas only 33% of similarly aged Caucasians are overweight (11). African-Americans are more insulin resistant than Caucasians (12, 13) even when adjusting for degree of obesity (14). There are some data suggesting that MI exists in African-American women. African-American males have higher fasting and 24-h respiratory quotients (RQs) than Caucasian males (15), and African-American postmenopausal females have lower postabsorptive fat oxidation rates than Caucasian counterparts (16). Differences in fat oxidation between African-Americans and Caucasians have been studied under varied conditions (postabsorptive, postprandial, or postexercise), and most (17, 18) but not all studies (19) have reported lower fat oxidation in African-American women.

In this paper, we analyze whether MI is present in premenopausal, nondiabetic, healthy African-American females. We report three studies. First we report substrate use measurements in response to eucaloric, macronutrient-manipulated diets: high fat (HF) vs. low fat (LF). We then report physiological mechanistic studies measuring differences in rates of substrate use in response to insulin infusion during pancreatic clamps and epinephrine infusion during lipolysis studies.


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
Studies overview

All studies were performed in the General Clinical Research Center at St. Luke’s-Roosevelt Hospital New York Obesity Research Center. Subjects signed consent forms for each experiment that was approved by the St. Luke’s-Roosevelt Institute for Health Sciences Institutional Review Board. Subjects were defined sedentary by physical activity questionnaires and completed an oral glucose tolerance test (75-g glucose load) to ensure absence of diabetes [mean fasting glucose, 5.0 mmol/liter (4.2–5.9 mmol/liter); mean 2-h glucose, 5.9 mmol/liter (4.1–8.3 mmol/liter)]. Subjects completed medical histories and physical exams and were excluded if they self-reported taking any medications including oral contraceptives or if they self-reported smoking within the past 6 months, consuming alcohol in excess (>2 oz. ethanol/d) or having irregular menstrual cycles (skipping more than two monthly cycles per year). Subjects were included if they self-reported all four grandparents were either from Caucasian or African ancestry. There was no overlap of subjects between studies.

Study 1

Twenty-one Caucasian and 21 African-American lean and obese [body mass index (BMI), 18.7–46.5 kg/m2], premenopausal (age 22–44 yr) women participated. Subjects had their resting metabolic rate (RMR) determined by indirect calorimetry as previously described (20) and provided with a 7-d eucaloric diet based upon their RMR adjusted for their activity level. Subjects were randomized to begin with either a LF (30% fat, 55% carbohydrate, 15% protein) or a HF (50% fat, 35% carbohydrate, 15% protein) diet. The fat calories were distributed as one third saturated, one third monounsaturated, and one third polyunsaturated for both diets. There was a minimum 2-wk washout period between the diets.

The subjects were provided with menus and 6-d food supplies to consume at home. Dietary compliance was assured through weight stability measurements, and adjustments were planned for a weight change of ±1 kg. However, because diets were based upon earlier RMR and physical activity measurements, adjustments were not necessary. On the sixth night, subjects were admitted to the General Clinical Research Center. Postabsorptive substrate use measurements were made through indirect calorimetry (Horizon Metabolic Cart or VMax29; Sensor Medics, Yorba Linda, CA) in 20 subjects [nine African-Americans (five obese and four lean) and 11 Caucasians (six obese and five lean)] (21) or by room calorimetry in 26 subjects [13 African-Americans (eight obese and five lean) and 13 Caucasians (seven obese and six lean)] (22). Fasting blood samples were collected after indirect calorimetry measurements.

Study 2

Nine Caucasian and nine African-American obese (BMI, 28.4–40.9 kg/m2), premenopausal (ages 26–49 yr) women participated in lipolysis studies at postabsorptive baseline followed by two-step (low- and high-dose insulin) pancreatic euglycemic clamps (21). Briefly, subjects were fed weight-maintaining diets for 3 d and on d 4 were studied. [1-13C]Palmitic acid (99% 13C; Masstrace, Woburn, MA) in an albumin mixture (Bayer Laboratories, Elkhart, IN) prepared as a sterile, pyrogen-free solution was infused [0.07 µmol/kg fat-free mass (FFM) per minute] from –90 min to +180 min. Somatostatin (Bachem, Torrence, CA) was infused (0.14 µg/kg FFM·min) starting at time 0 and lasting throughout the clamp (+180 min) to suppress endogenous insulin production. Exogenous insulin infusion (Humulin; Eli Lilly, Indianapolis, IN) was started at time 0 at 2 mU/m2·min and then at 90 min at 8 mU/m2·min until 180 min. Results from the lipolysis portion of the study have been previously published (21). Substrate use was measured at baseline and during the last 30 min of steady states of the two-step pancreatic euglycemic clamp via indirect calorimetry (Horizon Metabolic Measurement Cart; Sensor Medics).

Study 3

Eight Caucasian and nine African-American obese (BMI, 28.3–40.3 kg/m2), premenopausal (ages 26–48 yr) women participated in epinephrine-induced in vivo lipolysis studies. Palmitate turnover rates were measured using stable isotopically labeled tracers as described for study 2. At –90 min, a continuous infusion of [1-13C]palmitate (0.07 µmol/kg FFM·min in an albumin mixture) was started. At min 0, epinephrine, a mixed {alpha}- and ß-adrenergic agonist, was infused at a rate of 1.0 µg/min for a total of 90 min to measure its effect on stimulating a lipolytic response and subsequent fat use. The epinephrine was diluted in 0.9% normal saline containing 1 mg/ml ascorbic acid to prevent epinephrine degradation. Substrate use was measured during baseline and the last 30 min of epinephrine infusion via indirect calorimetry (Vmax29; Sensor Medics).

Body composition

Fat mass, FFM, and percent body fat were measured in studies 1 and 2 by dual-energy x-ray absorptiometry (23) and in study 3 by densitometry (24, 25). Adipose tissue areas, sc (SAT) and visceral (VAT) (L2–L3 level), were measured by magnetic resonance imaging in all studies as described (21).

Insulin sensitivity measurements

Baseline insulin sensitivity was measured during the follicular phase of the menstrual cycle in studies 2 and 3 via an iv glucose tolerance test using the Bergman minimal model (26).

Assays

For all studies, blood samples were immediately centrifuged, aliquoted, and frozen at –70 C. Insulin was measured by RIA (Linco Research, St. Charles, MO), glucose was measured by a Beckman glucose analyzer (Beckman, Fullerton, CA), and epinephrine was measured via HPLC (27). The interassay coefficients of variation for insulin, glucose, and epinephrine were 4.5, 3, and 6.2%, respectively.

Indirect calorimetry calculations

Substrate use was calculated for all studies based upon O2 consumption and CO2 production (28) as follows: fat oxidation (FO) = (1.67 x vO2) – (1.67 x vCO2), carbohydrate oxidation (CO) = (4.55 x vCO2) – (3.21 x vO2), and nonprotein respiratory quotient (NPRQ) = (vCO2/vO2).

Determination of [1-13C]palmitate enrichment in the plasma

In studies 2 and 3, plasma palmitate enrichment was measured using gas chromatography/isotope-ratio mass spectrometry as described (21).

Calculations. Steady-state appearance and disappearance rates of palmitate (Ra palmitate) were calculated using the mean enrichment values and tracer infusion rates as described (21). For study 2, FFA turnover rates (Ra FFA) were calculated as Ra of palmitate multiplied by the percentage of palmitate from total plasma FFA (21).

Statistics

Log-transformed values were used for variables that were not normally distributed. Paired t tests and ANOVA with repeated measures were used to determine significant differences between African-American and Caucasian subjects. For the different indirect calorimetry measurements (study 1), a categorical factor was used in all ANOVA. No significant interactions were observed, and results were pooled. Post hoc analysis was performed using Fisher’s least significant difference, with the significance level defined as {alpha} = 0.05. Analysis of covariance using a general linear model was used for all studies to adjust for difference of pertinent variables between groups. Statistica version 6.0 (Statsoft Inc., Tulsa, OK) was used for all analyses.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
Dietary intervention studies: study 1

The Caucasian and African-American women’s baseline characteristics were not significantly different (Table 1Go). There was a significant diet by race interaction for FO (P < 0.01, Fig. 1AGo) and CO (P < 0.01, Fig. 1BGo) but not NPRQ (P = 0.10, Fig. 1CGo).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Subject characteristics for studies 1 (LF and HF diets), 2 (pancreatic-euglycemic clamp), and 3 (epinephrine-stimulated lipolysis)

 

Figure 1
View larger version (10K):
[in this window]
[in a new window]
  		FIG. 1. A, FO rates; B, CO rates; C, NPRQ in Caucasian ({circ}) and African-American (•) women during HF and LF diets. A, The diet by race interaction was P < 0.01 and the change within Caucasian women was P < 0.01 and within African-American women was P = 0.86 (LF vs. HF); B, the diet by race interaction was P < 0.01 and the change within Caucasian women was P < 0.01 and within African-American women was P = 0.69; C, the diet by race interaction was P = 0.10 and the change within Caucasian women was P < 0.01 and within African-American women was P = 0.42.

 
Post hoc analyses showed only Caucasian women increased FO (164.7 ± 12.5 vs. 230.8 ± 11.6 µmol/min, P < 0.01; for African-American, 182.5 ± 13.4 vs. 181.4 ± 12.3 µmol/min, P = 0.86), decreased CO (736.5 ± 36.1 vs. 511.2 ± 44.7 µmol/min, P < 0.01; for African-American, 596.0 ± 38.7 vs. 635.5 ± 47.9 µmol/min, P = 0.69) and decreased NPRQ (0.872 ± 0.02 vs. 0.818 ± 0.01, P < 0.01; for African-American, 0.862 ± 0.02 vs. 0.849 ± 0.01, P = 0.42) when switching from LF to HF diet. Additionally, Caucasian women had significantly higher FO (P = 0.05) during HF diet and higher CO (P = 0.01) during LF diet.

The significant differences in substrate use described for Caucasian compared with African-American women retained a P < 0.05 after correcting for age, waist-to-hip ratio (WHR), BMI, percent body fat, FFM, fat mass, and VAT or SAT area.

When switching from a LF to HF diet, the Caucasian women trended toward increased fasting insulin (68.0 ± 10.2 vs. 76.2 ± 9.7 pM, P = 0.08) whereas African-American women significantly decreased fasting insulin (99.8 ± 10.1 vs. 89.6 ± 9.7 pM, P = 0.05). The diet by race interaction for fasting plasma insulin was significant (P = 0.02). There were no significant differences for glucose between diets or races (P > 0.8 for all analyses).

Pancreatic euglycemic clamp studies: study 2

The Caucasian and African-American women’s baseline physical characteristics were not significantly different (Table 1Go). The overall time point (baseline, low-dose insulin, high-dose insulin) by race interaction was significant for CO (P = 0.05) but not for FO (P = 0.40) or NPRQ (P = 0.25) (Fig. 2Go, A–C).


Figure 2
View larger version (12K):
[in this window]
[in a new window]
  		FIG. 2. A, FO rates; B, CO rates; C, NPRQ in Caucasian ({circ}) and African-American (•) women during pancreatic euglycemic clamp. A, The overall time point by race interaction was P = 0.40, and the overall race effect was P = 0.02; B, the overall time point by race interaction was P = 0.05; C, the overall time point by race interaction was P = 0.25, and the overall race effect was P = 0.01.

 
Caucasian women had higher FO (baseline 314.6 ± 36.0, low dose 361.4 ± 42.4, and high dose 304.0 ± 32.9 µmol/min vs. African-American baseline 155.8 ± 36.1, low dose 208.7 ± 42.3, and high dose 169.6 ± 32.9 µmol/min, P = 0.02) and lower NPRQ (baseline 0.743 ± 0.02, low dose 0.728 ± 0.03, and high dose 0.764 ± 0.02 vs. African-American baseline 0.828 ± 0.02, low dose 0.780 ± 0.01, and high dose 0.815 ± 0.02, P = 0.01) during the clamp. CO was significantly lower in the Caucasian women at baseline (311.1 ± 97.9 vs. African-American 663.5 ± 111.0 µmol/min, P = 0.04) but not different at low-dose insulin (220.9 ± 58.5 vs. African-American 314.5 ± 66.4 µmol/min, P = 0.43) or high-dose insulin (390.0 ± 62.9 µmol/min vs. African-Americans 449.8 ± 71.3 µmol/min, P = 0.38).

During low-dose insulin infusion, the Caucasian women did not change their FO (P = 0.07), CO (P = 0.29), or NPRQ (P = 0.37), whereas the African-American women had significantly increased FO (P = 0.02) and decreased CO (P < 0.01) and NPRQ (P < 0.01). During the high-dose insulin infusion, Caucasian women significantly suppressed FO (P < 0.01) and increased CO (P = 0.04) and NPRQ (P = 0.05), whereas the African-American women did not suppress FO (P = 0.11), although they increased CO (P = 0.05) and NPRQ (P = 0.05).

The significant differences in substrate use described for Caucasian compared with African-American women retained a P < 0.05 after correcting for age, WHR, BMI, percent body fat, FFM, fat mass, and VAT or SAT area.

There was no significant race effect or time point by race interaction for FFA turnover rate (µmol/min) (P = 0.73 and P = 0.64, respectively; Table 2Go). Both African-Americans and Caucasians significantly increased FFA turnover rate (~20%) from baseline (P < 0.01 for both races) to low-dose insulin and significantly decreased FFA turnover rate (~37%) when switched to high-dose insulin (P < 0.01 for both races).


View this table:
[in this window]
[in a new window]
  		TABLE 2. Substrate and hormone levels during study 2 (pancreatic euglycemic clamp)

 
There was an overall time point by race interaction for plasma insulin (P = 0.03) but not for plasma glucose (P = 0.70) (Table 2Go). African-American women had significantly higher plasma insulin levels during the high-dose insulin compared with baseline levels (P < 0.01), whereas the levels in Caucasian women did not differ (P = 0.29).

Epinephrine-induced lipolysis studies: study 3

The Caucasian and African-American women’s baseline physical characteristics were not significantly different (Table 1Go). The time point (baseline vs. final 30 min of epinephrine infusion) by race interaction was not significant for FO (P = 0.30, Fig. 3AGo) but was significant for CO (P = 0.01, Fig. 3BGo) and approached significance for NPRQ (P = 0.06, Fig. 3CGo).


Figure 3
View larger version (11K):
[in this window]
[in a new window]
  		FIG. 3. A, FO rates; B, CO rates; C, NPRQ in Caucasian ({circ}) and African-American (•) women during an epinephrine-induced lipolysis study. A, The time point by race interaction was P = 0.30, and the change within Caucasian women was P < 0.01 and within African-American women was P = 0.07; B, the time point by race interaction was P = 0.01, and the change within Caucasian women was P < 0.01 and within African-American was P = 0.20; C, the time point by race interaction was P = 0.06 and the change within Caucasian was P < 0.01 and within African-American women was P = 0.53.

 
Post hoc analysis found that only Caucasian women significantly increased FO (baseline 188.3 ± 35.5 vs. final 30 min 314.7 ± 44.0 µmol/min, P < 0.01; for African-American, baseline 148.0 ± 26.1 vs. final 30 min 230.7 ± 32.2 µmol/min, P = 0.07), decreased CO (baseline 1133.2 ± 104.3 vs. final 30 min 621.2 ± 99.6 µmol/min, P < 0.01; for African-American, baseline 1060.4 ± 102.7 vs. final 30 min 933.3 ± 101.1 µmol/min, P = 0.20) and decreased NPRQ (baseline 0.939 ± 0.02 vs. final 30 min 0.826 ± 0.03, P < 0.01; for African-American, baseline 0.916 ± 0.02 vs. final 30 min 0.896 ± 0.03, P = 0.53).

Caucasians’ CO and NPRQ trended toward being significantly lower after epinephrine infusion compared with African-American women (P = 0.09 and P = 0.06, respectively).

The significant differences in substrate use described for Caucasian compared with African-American women retained a P < 0.05 after correcting for age, WHR, BMI, percent body fat, FFM, fat mass, and VAT or SAT area.

The rate of palmitate appearance (Ra palmitate) was equal between races at baseline. Both groups increased their Ra palmitate in response to epinephrine (P = 0.01), and there was no difference in this increase between groups (P = 0.40) (Table 3Go).


View this table:
[in this window]
[in a new window]
  		TABLE 3. Substrate and hormone profile during study 3 (epinephrine-stimulated lipolysis)

 
There were no racial differences or interactions for plasma epinephrine, glucose, and insulin levels. Both African-Americans and Caucasians significantly increased their plasma epinephrine (P < 0.01) and glucose levels (P < 0.01) but did not significantly change their plasma insulin in response to epinephrine infusion (P > 0.1; Table 3Go).


   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
We performed multiple studies to examine whether MI exists in nondiabetic African-American females. We studied this topic because African-Americans have been reported to be more obese and insulin resistant than Caucasians (12, 13, 14). In each of our studies, our African-American subjects were similar in age and BMI compared with Caucasian subjects. These studies examined lean (study 1) and obese (studies 1, 2, and 3) premenopausal women who were nondiabetic and healthy.

We found increased postabsorptive FO and decreased CO and NPRQ in Caucasian women when switched from a LF to HF eucaloric diet; this was not observed in African-American women. Macronutrient manipulation of isocaloric diet studies have been shown to affect nutrient use through 24-h energy expenditure measurements in lean and obese populations (29). Using our paradigm of eucaloric macronutrient-manipulated diets, we found that African-American women were unable to switch their substrate use, and we believe that this phenomenon is equivalent to what has been described as MI (1, 2, 3, 4, 5).

The increased prevalence of insulin resistance in African-Americans (12, 13, 14) may be an underlying mechanism to explain the manifestation of MI. We did not directly measure peripheral insulin sensitivity during dietary intervention, limiting the interpretation of our data. However, insulin regulates many cellular pathways (30), and changes in its levels during dietary intervention may provide some insight into our findings.

The African-American women we studied had greater fasting plasma insulin during the LF diet compared with the HF diet, whereas the opposite response occurred in the Caucasian women. A similar finding has previously been reported with changes in insulin sensitivity between African-Americans and Caucasians during a comparable dietary intervention (31). Normally, elevated insulin levels suppress FFA levels and FO. We did not find differences in plasma FFA between races or diets (data not shown); thus the observed hyperinsulinemia in African-American women during LF diet failed to suppress FO. Obese adolescents were shown to increase their insulin secretion to maintain normoglycemia and metabolic flexibility under high-carbohydrate, isocaloric diets similar to our study (32). The higher insulin levels during the LF diet in the African-American women could have preserved their metabolic flexibility but failed.

During the HF diet, we expected the African-American women to increase their FO because of increased fat availability. Their response was contrary to our hypothesis and the Randle cycle, which assumes that in insulin-resistant subjects, increased FFA availability results in increased fatty acid use subsequently leading to impaired glucose oxidation (33). Our African-American women did not increase systemic FO or decrease CO during HF compared with LF diet. This finding supports hypotheses by Sidossis and Wolfe (34) and Mandarino et al. (35), which stated that carbohydrates remain the preferential substrate for muscle even during high FFA levels.

Although we did not find differences in plasma FFA levels between races or diets, differences in FFA turnover rates or FFA availability may have been present. Therefore, we turned to additional mechanistic studies to further identify differences in fat use and availability between African-American and Caucasian women.

During euglycemic clamp studies, the African-American women did not suppress systemic FO in response to the high-dose insulin infusion similarly to the Caucasian women despite the African-American women doubling their baseline plasma insulin. In fact, the African-American women increased FO and decreased CO only when their insulin levels were below basal levels (low-dose infusion). When plasma epinephrine levels were in physiological ranges favoring fat use (36), the African-American women did not significantly increase their FO but rather maintained significantly greater CO compared with Caucasian women. Epinephrine could be promoting glycogenolysis and gluconeogenesis (37) in addition to lipolysis.

Despite differences in substrate use in both of our mechanistic studies, FFA availability, measured as FFA turnover rate or Ra palmitate, at baseline and their response to insulin or epinephrine did not differ between African-American and Caucasian women. However, although systemic FFA turnover rates during the two diets may not have differed in African-Americans compared with Caucasians, lipid distribution in the muscle could have differed. African-American women tend to have greater intermuscular adipose tissue compared with Caucasian women (14) and may store fat ectopically as intramyocellular lipids (IMCL) (13). Myocytes rapidly increase IMCL in response to dietary fat (38). In African-American women, the lack of increase in FO during HF diet creates a metabolic profile favoring fat storage. Elevated IMCL is associated with insulin resistance (39); therefore, the relationship between this ectopic fat deposition, increased prevalence of insulin resistance, and MI in African-American women needs to be further explored.

Our design did not include a direct measure of circulating FFA oxidation. Therefore, we can only speculate whether the FFA oxidation we measured by indirect calorimetry represented oxidation of circulating vs. stored fat. Sumner et al. (40) demonstrated lower triglyceride levels in African-American women compared with African-American men and hypothesized that decreased adipose tissue FFA release explained this observation. However, we have previously reported in the Caucasians and African-Americans from study 2 no significant differences in basal or insulin-suppressed FFA release in relation to their regional adipose tissue distribution (VAT and SAT) (21), nor did we find any differences in study 3. Additional analysis of FFA kinetics in studies 2 and 3 showed that FFA clearance (calculated as the Ra FFA or Ra palmitate divided by the plasma FFA or palmitate concentration, respectively) was slightly lower but not significantly different in Caucasian vs. African-American women (0.72 ± 0.10 vs. 0.84 ± 0.09 liter/min, P = 0.37, for study 2 and 0.90 ± 0.12 liter/min vs. 1.16 ± 0.09, P = 0.11, for study 3). We can therefore only speculate that the defect in substrate use in the African-American group may be occurring on an intracellular level.

Other factors may have affected substrate use during our dietary intervention study. We examined whether leptin and adiponectin, adipokines that affect insulin sensitivity and substrate use, were altered. We measured levels of these adipokines in a subset of women but found no differences between races or diets (data not shown).

Our study has some limitations. Each of the three studies examined different sets of Caucasian and African-American women, which may limit the overall interpretation of our data. However, within each study, our subjects had similar characteristics, and we repeatedly observed impaired substrate use after correcting for measurable differences in body composition, further substantiating our finding of MI in African-American women. In addition, the Caucasian and African-American women in studies 2 and 3 had similar baseline insulin sensitivity, suggesting that MI may exist before the development of insulin resistance. Moreover, we did not measure intermuscular adipose tissue or IMCL, and how these adipose tissue depots contribute toward MI remains unknown. Finally, in study 1, we did not control for follicular phase of the menstrual cycle in all women. However, we did control for follicular phase in a subset of women (six African-Americans and seven Caucasians), and similar substrate use results were observed.

In summary, we found that healthy, premenopausal, nondiabetic Caucasian women are more systemically, metabolically flexible than their African-American counterparts. African-American women failed to switch fat and carbohydrate use based upon dietary macronutrient composition. Disordered substrate use may explain these findings; African-Americans favored fat storage, whereas Caucasians favored fat use. These studies may help explain why African-American women are at increased risk for the development of obesity and type 2 diabetes compared with Caucasian women.


   Acknowledgments
 
We thank all of the women who participated in these studies.


   Footnotes
 
This work was supported by National Institutes of Health Grants R01 DK40414, M01RR00645, and P30DK26687 and the American Diabetes Association Grant 1-05-RA-03.

First Published Online July 25, 2006

Abbreviations: BMI, Body mass index; CO, carbohydrate oxidation; FFA, free fatty acids; FFM, fat-free mass; FO, fat oxidation; HF, high-fat; IMCL, intramyocellular lipids; LF, low-fat; MI, metabolic inflexibility; NPRQ, nonprotein respiratory quotient; Ra, appearance rate; RMR, resting metabolic rate; RQ, respiratory quotient; SAT, sc adipose tissue; VAT, visceral adipose tissue; WHR, waist-to-hip ratio.

Received November 4, 2005.

Accepted July 13, 2006.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Kelley DE, Goodpaster BH, Wing RR, Simoneau JA 1999 Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity and weight loss. Am J Physiol 277:E1130–E1141
  2. Kelley DE, Goodpaster BH, Storlien LH 2002 Muscle triglycerides and insulin resistance. Annu Rev Nutr 22:325–346[CrossRef][Medline]
  3. Kelley DE, Mandarino LJ 2000 Fuel selection in human skeletal muscle in insulin resistance. Diabetes 49:677–683[Abstract]
  4. Storlien L, Oakes ND, Kelley DE 2004 Metabolic inflexibility. Proc Nutr Soc 63:363–368[CrossRef][Medline]
  5. Kelley DE 2002 Skeletal muscle triglycerides: an aspect of regional adiposity and insulin resistance. Ann NY Acad Sci 967:135–145[CrossRef][Medline]
  6. Treuth M, Sunehag A, Trautwein L, Bier D, Haymond M, Butte N 2003 Metabolic adaptation to high-fat and high carbohydrate diets in children and adolescents. Am J Clin Nutr 77:479–489[Abstract/Free Full Text]
  7. Roy H, Lovejoy J, Keenan, Bray G, Windhauser M, Wilson J 1998 Substrate oxidation and energy expenditure in athletes and non-athletes consuming isoenergetic high- and low-fat diets. Am J Clin Nutr 67:405–411[Abstract]
  8. Smith S, de Jonge L, Zachweiga JJ, Roy H, Nguyen T, Rood J, Windhauser M, Bray G 2000 Fat and carbohydrate balances during adaptation to a high-fat diet. Am J Clin Nutr 71:450–457[Abstract/Free Full Text]
  9. Ukropcova B, McNeil M, Sereda O, de Jonge L, Xie H, Bray G, Smith S 2005 Dynamic changes in fat oxidation in human primary myocytes mirror metabolic characteristics of the donor. J Clin Invest 115:1934–1941[CrossRef][Medline]
  10. National Center for Health Statistics 1981 Plan and operation of the Health and Nutrition Examination Survey, United States, 1976–1980: vital and health statistics. DHHS Pub. No. (PHS)81-1317, Series 1, No. 15. Washington, DC: Public Health Service, U.S. Government Printing Office
  11. Kuczmarski R, Flegal K, Campbell S, Johnson C 1995 Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys: 1969 to 1991. JAMA 272:205–211
  12. Haffner S, D’Agostino R, Saad M, Rewers M, Mykkannen L, Selby J, Howard G, Savage P, Hamman R, Wagenknecht LE, Bergman R 1996 Increased insulin resistance and insulin secretion in non-diabetic African Americans and Hispanics compared to non-Hispanic whites. Diabetes 45:742–748[Abstract]
  13. Ryan A, Nicklas B, Berman D 2002 Racial differences in insulin resistance and mid thigh fat deposition in post menopausal women. Obes Res 10:336–344[Medline]
  14. Albu J, Kovera A, Allen L, Wainwright M, Berk E, Raja-Khan N, Janumala I, Burkey B, Heshka S, Gallagher D 2005 Independent association of insulin resistance with increased inter-muscular adipose tissue and larger acute insulin response to glucose in African American vs. Caucasian non-diabetic women. Am J Clin Nutr 82:1210–1217[Abstract/Free Full Text]
  15. Weyer C, Snitker S, Bogardus C, Ravussin E 1999 Energy metabolism in African Americans: potential risk factors for obesity. Am J Clin Nutr 70:13–20[Abstract/Free Full Text]
  16. Nicklas BJ, Berman DM, Davis DC, Dobrovolny CL, Dennis KE 1999 Racial differences in metabolic predictors of obesity among postmenopausal women. Obes Res 7:463–468[Medline]
  17. Hickner R, Privette J, McIver K, Barakat H 2001 Fatty acid oxidation in African-American and Caucasian women during physical activity. J Appl Physiol 90:2319–2324[Abstract/Free Full Text]
  18. Chitwood L Brown S, Lundy M, Dupper M 1996 Metabolic propensity towards obesity in black vs. white females: response during rest, exercise and recovery. Int J Obes 20:455–462[Medline]
  19. Melby C, Ho Jeckel K, Goran M, Donahoo W 2000 Comparison of risk factors for obesity in young, nonobese African American and Caucasian women. Int J Obes 24:1514–1522[CrossRef][Medline]
  20. Albu J, Shur M, Curi M, Murphy L, Heymsfield, Pi-Sunyer FX 1997 Resting metabolic rate in obese, pre-menopausal black women. Am J Clin Nutr 66:531–538[Abstract/Free Full Text]
  21. Albu J, Curi M, Shur M, Murphy L, Matthews D, Pi-Sunyer FX 1999 Systemic resistance to the antilipolytic effect of insulin in black and white women with visceral obesity. Am J Physiol 277:E551–E560
  22. Zhang K, Sun M, Werner P, Kovera A, Albu J, Pi-Sunyer FX, Boozer C 2002 Sleeping metabolic rate in relation to body mass index and body composition. Int J Obes 26:376–383[CrossRef][Medline]
  23. Siri W 1961 Body composition from fluids and density: analysis of methods. In: Brozek J, Henschel A, eds. Techniques for measuring body composition. Washington, DC: National Academy of Science
  24. Sopher A, Thorton J, Wang J, Pierson R, Heymsfield S, Horlick M 2004 Measurements of percentage of body fat in 411 children and adolescents: a comparison of dual energy X-ray absorptiometry with a four compartment model. Pediatrics 113:1285–1290[Abstract/Free Full Text]
  25. Nunez C, Kovera AJ, Pietrobelli A, Heshka S, Horlick M, Kehayais JJ, Wang Z, Heymsfield S 1999 Body composition in children and adults by air displacement plethysmography. Eur J Clin Nutr 53:382–387[CrossRef][Medline]
  26. Bergman R, Beard J, Chen M 1986 The minimal modeling method: assessment of insulin sensitivity and ß-cell function in vivo. In: Larner J, Pohl S, eds. Methods in clinical diabetes research. New York: Wiley International; 13–20
  27. Neilsen S, Guo Z, Albu J, Klien S, O’Brien P, Jensen M 2003 Energy expenditure, sex, and endogenous fuel availability in humans. J Clin Invest 11:981–988
  28. White M, Bouchard G, Buemann B, Almeras N, Després J, Bouchard C, Tremblay A 1996 Reproducibility of 24-hr energy expenditure and macronutrient oxidation rates in an indirect calorimeter. J Appl Physiol 80:133–139[Abstract/Free Full Text]
  29. Shah M, Garg A 1996 High-fat and high-carbohydrate diets and energy balance. Diabetes Care 19:1142–1152[Abstract]
  30. Coppack S, Frayn K, Humphreys S, Dhar H, Hockaday T 1989 Effects of insulin on human adipose tissue metabolism in vivo. Clin Sci 77:663–670
  31. Lovejoy J, Windhauser M, Rood J, de la Bretonne J 1998 Effect of a controlled high-fat versus low-fat diet on insulin sensitivity and leptin levels in African-American and Caucasian women. Metabolism 47:1520–1524[CrossRef][Medline]
  32. Sunehag A, Toffolo G, Campioni M, Bier D, Haymond M 2005 Effects of dietary macronutrient intake on insulin sensitivity and secretion and glucose and lipid metabolism in healthy, obese adolescents. J Clin Endocrinol Metab 90:4496–4502[Abstract/Free Full Text]
  33. Randle P, Garland P, Hales C, Newsholme E1963 The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785–789
  34. Sidossis L, Wolfe R 1996 Glucose and insulin induced inhibition of fatty acid oxidation: the glucose-fatty acid cycle reversed. Am J Physiol 270:E733–E738
  35. Mandarino L, Consoli A, Jain A, Kelley D 1996 Interaction of carbohydrate and fat fuels in human skeletal muscle: impact of obesity and NIDDM. Am J Physiol 270:E463–E470
  36. Samra J, Simpson E, Clark M Forster C, Humphreys S, Macdonald I, Frayn K 1996 Effects of epinephrine infusion on adipose tissue: interactions between blood flow and lipid metabolism. Am J Physiol 271:E834–E839
  37. Sherwin R, Sacca L 1984 Effect of epinephrine on glucose metabolism in humans: contribution of the liver. Am J Physiol 247:E157–E165
  38. Bachmann O, Dahl D, Bretchel K, Machann J, Haap M, Maier T, Loviscach M, Stumvoll M, Claussen C, Schick F, Haring H, Jacob S 2001 Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 50:2579–2584[Abstract/Free Full Text]
  39. Krssak M, Petersen K, Dresner A, Dipietro L, Vogel S, Rothman D, Shulman G, Roden M 1999 Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42:113–116[CrossRef][Medline]
  40. Sumner A, Kushner H, Tulenko T, Falkner B, Marsh J 1997 The relationship in African Americans of sex differences in insulin-mediated suppression of non-esterified acids to sex differences in fasting triglyceride levels. Metabolism 46:400–405[CrossRef][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berk, E. S.
Right arrow Articles by Albu, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berk, E. S.
Right arrow Articles by Albu, J. B.
Related Collections
Right arrow Metabolism

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals